Diese Webseite nutzt Cookies zur Verbesserung des Erlebnisses unserer Besucher. Indem Sie weiterhin auf dieser Webseite navigieren, erklären Sie sich mit unserer Verwendung von Cookies einverstanden.
Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective
On behalf of ITM I would like to invite you to our NulkearMedizin 2022 Symposium “Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective” on Thursday, 28. April 2022, 12:30 - 13:30 pm, room 2 at the Leipzig Congress Centre.
Our symposium will be chaired by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, and the faculty will consist of Prof. Dr. Wolfgang Wadsak, Head of Medicinal Radiochemistry and Biomarker Development, Medical University of Vienna, and Neil Quigley, Global Product Manager, ITM.
The in-house preparation of radiopharmaceuticals has resulted in major developments in the field of nuclear medicine and precision oncology, including the development of prostate cancer and neuroendocrine tumor treatment. The symposium will provide an introduction and overview of the current status of in-house preparation with some recent developments that can be attributed to it.
I look forward to you joining us in what promises to be an exciting overview of recent developments and radiopharmacy perspective with critical analysis of the latest science and clinical practice that is driving the Targeted Radionuclide Therapy paradigm into the forefront of patient management.
Steffen Schuster, CEO ITM
Program
Chair: Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich
Recent Developments: New Targets and Emerging 225Ac-Therapies Neil Quigley, Global Product Manager, ITM, Munich
Die Herstellung von Radiopharmaka zur unmittelbaren Anwendung – essentieller Baustein und Innovationstreiber in der Nuklearmedizin Prof. Wolfgang Wadsak, Leiter der Medizinischen Radiochemie und Biomarkerentwicklung der klinischen Abteilung für Nuklearmedizin, Universitätsklinikum AKH Wien
Serving Future Global Demand of n.c.a. 177Lu and Development of 225Ac Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich
